Kiniksa Begin Period Cash Flow vs Free Cash Flow Analysis
KNSA Stock | USD 21.41 0.09 0.42% |
Kiniksa Pharmaceuticals financial indicator trend analysis is infinitely more than just investigating Kiniksa Pharmaceuticals recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Kiniksa Pharmaceuticals is a good investment. Please check the relationship between Kiniksa Pharmaceuticals Begin Period Cash Flow and its Free Cash Flow accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kiniksa Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. For information on how to trade Kiniksa Stock refer to our How to Trade Kiniksa Stock guide.
Begin Period Cash Flow vs Free Cash Flow
Begin Period Cash Flow vs Free Cash Flow Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Kiniksa Pharmaceuticals Begin Period Cash Flow account and Free Cash Flow. At this time, the significance of the direction appears to have weak contrarian relationship.
The correlation between Kiniksa Pharmaceuticals' Begin Period Cash Flow and Free Cash Flow is -0.03. Overlapping area represents the amount of variation of Begin Period Cash Flow that can explain the historical movement of Free Cash Flow in the same time period over historical financial statements of Kiniksa Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Kiniksa Pharmaceuticals' Begin Period Cash Flow and Free Cash Flow is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Begin Period Cash Flow of Kiniksa Pharmaceuticals are associated (or correlated) with its Free Cash Flow. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Free Cash Flow has no effect on the direction of Begin Period Cash Flow i.e., Kiniksa Pharmaceuticals' Begin Period Cash Flow and Free Cash Flow go up and down completely randomly.
Correlation Coefficient | -0.03 |
Relationship Direction | Negative |
Relationship Strength | Insignificant |
Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Free Cash Flow
The amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.Most indicators from Kiniksa Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Kiniksa Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kiniksa Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. For information on how to trade Kiniksa Stock refer to our How to Trade Kiniksa Stock guide.The current year's Selling General Administrative is expected to grow to about 125.9 M, whereas Tax Provision is forecasted to decline to (5.8 M).
2021 | 2022 | 2023 | 2024 (projected) | Interest Income | 97K | 1.3M | 1.1M | 1.6M | Net Interest Income | 97K | 1.3M | 1.1M | 1.6M |
Kiniksa Pharmaceuticals fundamental ratios Correlations
Click cells to compare fundamentals
Kiniksa Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Kiniksa Pharmaceuticals fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 254.5M | 349.5M | 232.8M | 459.7M | 526.3M | 309.2M | |
Other Current Liab | 25K | 27.1M | 36.2M | 32.6M | 50.6M | 27.0M | |
Total Current Liabilities | 27.8M | 31.8M | 44.8M | 47.1M | 63.7M | 38.2M | |
Total Stockholder Equity | (356.1M) | (517.5M) | (675.4M) | (492.0M) | 438.8M | 460.8M | |
Net Tangible Assets | 225.4M | 311.9M | 194.5M | 377.9M | 434.6M | 456.3M | |
Property Plant And Equipment Net | 8.3M | 10.6M | 8.4M | 7.0M | 12.7M | 7.4M | |
Net Debt | (44.3M) | (107.1M) | (116.4M) | (116.8M) | (95.7M) | (100.5M) | |
Retained Earnings | (356.1M) | (517.5M) | (675.4M) | (492.0M) | (478.0M) | (501.8M) | |
Accounts Payable | 5.7M | 503K | 1.9M | 7.9M | 8.2M | 5.0M | |
Cash | 46.9M | 114.0M | 122.5M | 122.7M | 108.0M | 126.9M | |
Non Current Assets Total | 12.9M | 16.2M | 36.4M | 216.6M | 250.0M | 262.5M | |
Non Currrent Assets Other | 210K | 5.6M | 8.7M | 5.8M | 827K | 785.7K | |
Other Assets | 4.6M | 12.2M | 8.7M | 191.3M | 1.0 | 0.95 | |
Cash And Short Term Investments | 233.4M | 323.5M | 182.2M | 190.6M | 206.4M | 212.4M | |
Common Stock Total Equity | 13K | 15K | 18K | 19K | 21.9K | 13.4K | |
Common Stock Shares Outstanding | 54.0M | 61.8M | 68.6M | 70.4M | 71.9M | 57.9M | |
Short Term Investments | 186.5M | 209.4M | 59.7M | 67.9M | 98.4M | 117.9M | |
Liabilities And Stockholders Equity | (327.0M) | (479.9M) | (627.6M) | (428.5M) | 526.3M | 552.6M | |
Non Current Liabilities Total | 1.3M | 5.7M | 2.9M | 16.5M | 23.8M | 25.0M | |
Capital Surpluse | 581.5M | 829.4M | 860.5M | 888.1M | 1.0B | 571.2M | |
Other Current Assets | 8.2M | 9.8M | 13.2M | 10.5M | 17.5M | 9.3M | |
Other Stockholder Equity | (48K) | 829.4M | 860.5M | 888.1M | 916.8M | 480.8M | |
Total Liab | 29.1M | 37.5M | 47.8M | 63.5M | 87.5M | 52.8M | |
Property Plant And Equipment Gross | 8.3M | 10.6M | 14.3M | 13.9M | 20.5M | 21.5M | |
Total Current Assets | 241.6M | 333.2M | 196.4M | 243.1M | 276.3M | 234.8M | |
Accumulated Other Comprehensive Income | 33K | (34K) | (66K) | 44K | 6K | 6.3K | |
Common Stock | 13K | 15K | 18K | 19K | 20K | 14.4K | |
Property Plant Equipment | 8.3M | 4.1M | 2.8M | 1.7M | 1.9M | 3.7M | |
Net Invested Capital | 225.4M | 311.9M | 185.0M | 396.1M | 438.8M | 274.5M | |
Net Working Capital | 213.8M | 301.4M | 151.6M | 196.0M | 212.6M | 216.3M | |
Other Liab | 326K | 805K | 270K | 13.8M | 15.9M | 16.7M | |
Retained Earnings Total Equity | (356.1M) | (517.5M) | (675.4M) | (492.0M) | (442.8M) | (465.0M) | |
Non Current Liabilities Other | 326K | 5.7M | 2.9M | 16.5M | 1.9M | 1.8M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Kiniksa Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Kiniksa Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Kiniksa Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Kiniksa Pharmaceuticals Stock:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kiniksa Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. For information on how to trade Kiniksa Stock refer to our How to Trade Kiniksa Stock guide.You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kiniksa Pharmaceuticals. If investors know Kiniksa will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kiniksa Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 5.5 | Earnings Share (0.12) | Revenue Per Share 5.415 | Quarterly Revenue Growth 0.674 | Return On Assets (0.03) |
The market value of Kiniksa Pharmaceuticals is measured differently than its book value, which is the value of Kiniksa that is recorded on the company's balance sheet. Investors also form their own opinion of Kiniksa Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Kiniksa Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kiniksa Pharmaceuticals' market value can be influenced by many factors that don't directly affect Kiniksa Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kiniksa Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Kiniksa Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kiniksa Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.